{
    "url_original": "https://www.wsj.com/articles/j-j-contractor-plans-to-resume-covid-19-vaccine-production-at-troubled-baltimore-plant-11627528043?mod=business_lead_pos3",
    "url": "j-j-contractor-plans-to-resume-covid-19-vaccine-production-at-troubled-baltimore-plant-11627528043",
    "title": "J&J Contractor Plans to Resume Covid-19 Vaccine Production at Troubled Baltimore Plant",
    "sub_head": "Emergent BioSolutions received FDA approval to resume manufacturing after being shut down for contamination",
    "category_1": "Business",
    "time": "2021-07-28 23:07:00",
    "body": "WASHINGTON— Emergent BioSolutions Inc.  plans to resume Covid-19 vaccine production at its Baltimore plant after getting the green light from the Food and Drug Administration, according to a statement from the company and an FDA letter reviewed by the Journal.<br />“We are proud to be resuming production of bulk Covid-19 vaccine batches following additional reviews and collaboration with FDA and our manufacturing partners,” Emergent CEO Robert Kramer said in a statement late Wednesday. “We are grateful for the opportunity to help bring this global pandemic to an end.”<br />The plant makes vaccines for  Johnson & Johnson .<br />While domestic demand for the Johnson & Johnson shot has dwindled in recent months, the Biden administration is seeking the shots to be exported to countries needing protection against Covid-19.<br />The Baltimore plant had been shut down after FDA inspectors determined there was severe contamination at the plant."
}